Heterocyclic Compounds

Matches 501 - 550 out of 30,869	< 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 >

Document	Document Title
WO/2023/078271A1	AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Disclosed are an aromatic compound, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof, specifically relating to an aromatic compound shown in formula I, a tautomer, stereoisom...
WO/2023/080652A1	ANDROGEN RECEPTOR DEGRADERS FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND USE THEREOF Described herein novel compounds as androgen-receptor inhibitors for the treatment of prostate cancer and use thereof.
WO/2023/078337A1	CDK8/19 DUAL INHIBITORS AND METHODS OF USE The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19. In one aspect, described herein are compounds of Formula (A'), (A), (A-I), (A-II), (II), (II-I), (II-II), (III), (B), (IV), (V), (VI), and (VII), and...
WO/2023/081441A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hy...
WO/2023/077726A1	ORGANIC COMPOUND, LIGHT EXTRACTION LAYER MATERIAL, AND ORGANIC ELECTRONIC DEVICE The present invention provides an organic compound, a light extraction layer material, and an organic electronic device. The structure of the organic compound is represented as general formula (1). The organic compound can be used as the...
WO/2023/077678A1	SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a small molecule compound targeting an SRSF6 protein and a preparation method therefor and a use thereof. The compound is as represented by formula (I). A molecule can selectively inhibit abnormal c...
WO/2023/076237A1	COMPOUNDS AS GLP-1R AGONISTS The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...
WO/2023/072962A1	SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB-inducing kinase (NIK) inhibitors and, in particular, can induce the ...
WO/2023/076626A1	RXFP1 AGONISTS The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
WO/2023/074847A1	NOVEL SPIRO COMPOUND The present invention provides: a novel spiro compound having a TRH-DE inhibition activity and useful for the prevention/treatment of various diseases associated with TRH and/or symptoms associated with the diseases, or a pharmacological...
WO/2023/072966A1	IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 The present invention relates to a compound of formula (I) wherein R1 represents a (C4-C6)alkyl group, a (C3-C8)cycloalkyl group, a bridged (C6-C10)cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherei...
WO/2023/076615A1	CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS The present disclosure relates to methods for treating chronic rhinosinusitis with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (I) or a pharma...
WO/2023/072969A1	IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 The present invention relates to a compound of formula (I) wherein A, B, C, D and E are selected from the group consisting of =CH- and -N=, R2 is selected from a hydrogen atom, a (C1-C4)alkyl group and a (C3-C6)cycloalkyl group, R1 repre...
WO/2023/074767A1	AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME The purpose of the present invention is to provide a compound which absorbs light having a wavelength of 400 nm to 410 nm from sunlight, does not affect a material inside an organic EL element, and has a high refractive index in a wavele...
WO/2023/072961A1	IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 The present invention relates to a compound of formula (I) wherein R2 is selected from the group consisting of a hydrogen atom and a (C1-C3)alkyl group, R3 is a (C1-C4)alkyl or a (C3-C6)cycloalkyl group, R1 represents a (C4-C6)alkyl grou...
WO/2023/071073A1	ARYLAMINE ORGANIC COMPOUND AND USE THEREOF The present application discloses an arylamine organic compound and the use thereof. The arylamine organic compound has a structure as shown in general formula (1). The arylamine organic compound has a relatively high glass transition te...
WO/2023/073364A1	TETRAHYDROISOQUINOLINE COMPOUNDS THAT ARE KEAP1 BINDERS The present invention relates to tetrahydroisoquinoline compounds that are KEAP1 binders and their incorporation in bifunctional compounds which are capable of acting as proteolysis-targeting chimeras. The present invention also relates ...
WO/2023/065182A1	BENZOTHIAZINONE DERIVATIVE BASED ON ALKYNYL LINKING ARM, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a benzothiazinone derivative based on an alkynyl linking arm, a preparation method therefor, and a use thereof. The present invention is an inventive improvement on the position of a side chain connected to the skeleton of ...
WO/2023/067021A1	A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF The present invention relates to a new scheme and process for the preparation of one specific SIK3 inhibiting compound known as (and described herein as) "E9". Compound E9 has previously been described by the present applicant to show su...
WO/2023/069545A1	5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
WO/2023/068200A1	FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR Provided are: a novel fluorine-containing pyrazole compound having a halogen atom, an oxygen-containing substituent, or a nitrogen-containing substituent at the 3-position, a trifluoromethyl group at the 4-position, and an oxygen-contain...
WO/2023/068881A1	ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient, the aryl or heteroaryl derivative and the pharmaceutical composition being for the treatment of k...
WO/2023/069700A1	COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.
WO/2023/069544A1	5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
WO/2023/067515A1	THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS Disclosed herein are certain thiadiazolyl derivatives Formula (I): (I) that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclose...
WO/2023/070076A1	COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION The expression of the P-glycoprotein (P-gp) eﬄux transporter at the blood−brain interface impedes BBB penetrance of most small molecules. Designing eﬄux liabilities out of compounds can be laborious and there is no generalizable ap...
WO/2022/098970A9	PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds o...
WO/2023/060489A1	10-SUBSTITUTED-1-AZAPHENOTHIAZINE DERIVATIVE AND APPLICATION THEREOF A 10-substituted-1-azaphenothiazine derivative and an application thereof. The structure of the derivative is as represented by formula (I), and the definitions of respective substituents are as described in the description and the claim...
WO/2023/064058A1	TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS Compounds of formula I, that modulate DCAF15 and induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity ...
WO/2023/063751A1	COMPOUNDS INHIBITING ALK AND/OR EGFR MUTATION KINASES AND MEDICAL USE THEREOF The present disclosure provides novel compounds exhibiting inhibitory activity against ALK overexpression, ALK mutation, EGFR overexpression, EGFR mutation, etc., and a medical use thereof. The present disclosure provides a pharmaceutica...
WO/2023/061372A1	MALATE SALT OF XANOMELINE DERIVATIVE, CRYSTALLINE FORM A, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to the field of medicinal chemistry, and in particular, to a malate salt of a xanomeline derivative, the malate salt having a structure as shown in formula (I). The malate salt of the compound of formula (I)...
WO/2023/061440A1	MODIFIED PROTEINS AND PROTEIN DEGRADERS Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are bifunctional compounds having a DNA damage-binding protein 1 (DDB1) binding moiety, a linker, a...
WO/2023/064326A1	METHODS OF TREATING DISEASES ASSOCIATED WITH SENESCENT CELL ACCUMULATION Disclosed herein are methods of treating diseases and disorders associated with senescent cell accumulation (e.g., an age-related disease and/or liver disease, e.g., obesity, liver steatosis, non-alcoholic steatohepatitis (NASH), liver f...
WO/2023/064880A1	COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/061478A1	TRICYCLIC COMPOUND Provided in the present disclosure are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, a composition thereof, and the use thereof in the preparation of a drug for treating diseases related to CRBN...
WO/2023/063701A1	NOVEL COMPOUND FOR CAPPING LAYER, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
WO/2023/060573A1	NOVEL THIADIAZOLYL DERIVATIVES OF DNA POLYMERASE THETA INHIBITORS Poly theta inhibitor (I), X is -N-or -C-; ring A is phenyl or a five to ten membered heteroaryl ring containing, inclusive of X, one to four heteroatoms independently selected from nitrogen, oxygen, or sulfur, Ar1 is phenyl, heteroaryl, ...
WO/2023/062575A1	CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS Disclosed herein are certain succinamido derivatives of Formula (I): (I) that inhibit Wemer Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are thereofore useful in treating c...
WO/2023/061415A1	THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
WO/2023/061051A1	SULFAMIDE USP8 INHIBITOR AND USE THEREOF Disclosed in the present application are a class of compounds containing a thiazole or thiadiazole structure and the use thereof, which belong to the technical field of medicine. According to the present application, the structure of a l...
WO/2023/059583A1	HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
WO/2023/059873A1	MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS Provided herein are compounds of formula (I) and compositions thereof for modulating CAMKK2. In some embodiments, the compounds and compositions are provided for treatment of cancer and/or obesity.
WO/2023/059581A1	HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
WO/2023/060202A1	JANUS KINASE INHIBITING PYRAZOLE COMPOUNDS AND USES THEREOF Provided herein are pyrazole compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are us...
WO/2023/059899A1	FUSED BICYCLIC SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
WO/2023/050007A1	N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA Disclosed are compounds of formula (I), wherein V is N or CR; W is optionally substituted alkylene, alkenylene, alkynylene, cycloalkylene, or arylene; X is optionally substituted heterocyclylene, heteroarylene, arylene, wherein X may be ...
WO/2023/051134A1	METAL IRIDIUM COMPLEX AND APPLICATION THEREOF The present invention relates to an organometallic iridium compound and an application thereof. The organometallic iridium compound has a general formula of Ir(La)(Lb)(Lc), wherein La has the structure as shown in formula (1), and Lb has...
WO/2023/054715A1	METHOD FOR FORMING BOND THROUGH COUPLING REACTION The present invention provides a method for producing a compound through a cross-coupling reaction, wherein: the method for producing a compound includes reacting a compound 1 having a leaving group X1 on a carbon atom of an aromatic rin...
WO/2023/055763A2	SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTRAL CANCER Treatment of CHD1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers using CHD1L inhibitors. Small molecule inhibitors of CHDL1 which inhibit CHD1L ATPase and inhibit CHD1L-dependent TCF-transcription have...
WO/2023/051495A1	ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF The present invention relates to isoquinolinone and quinazolinone compounds as represented by formula (I) or (II), a pharmaceutical composition containing the compounds, and the use of the compounds and the pharmaceutical composition the...

Matches 501 - 550 out of 30,869	< 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 >